GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of [Paper] receptor distribution and why the GI effects were predictable — 25 comments in the full submission. View in context.
305
c/glp1science·submitted 7 days ago by u/sig_figs_sam

[Paper] receptor distribution and why the GI effects were predictable

Paperbranch of 6 comments

Trying to settle this properly because the thread from last year went in circles. The claim: gastric emptying matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 14 months without either producing anything. What would actually settle it is 21 people measuring…

Read the full submission and all 25 comments →

This branch

6 comments, started 6 days ago
u/flair_enthusiast33 points·6 days ago

The pharmacology literature is interesting but rodent models do not scale linearly to human dosing.

replysharereportpermalink
u/sig_figs_samOPmod · analytical48 points·5 days ago

Strongly agree. Central appetite is real but people overstate it.

replysharereportpermalink
u/tomas_lundgren16 points·6 days ago

the half-life is half-life, affects steady state timing

replysharereportpermalink
u/ismael_chukwu12 points·5 days ago

the 10-day half-life means week 10 is still ramp-up pharmacokinetically

replysharereportpermalink
u/sig_figs_samOPmod · analytical6 points·5 days ago

the 10-day half-life means week 10 is still ramp-up pharmacokinetically

Counter-anecdote: opposite result, same dose. Which mostly tells us the variance is huge.

replysharereportpermalink
u/nadia_bakker3 points·4 days ago

cite the paper: journal, year, first author, links optional

replysharereportpermalink

← back to the whole thread

About c/glp1science

The mechanism layer: incretin physiology, receptor distribution, gastric emptying, central appetite signalling, glucagon-receptor contribution, amylin co-agonism, and the pharmacokinetics that make weekly dosing possible. Papers get cited by journal and year or they get a [needs source] reply.

50kmembers
95submissions
Oct 2023created
submissions / month, last year
Sponsored

PeptideMeter Analytics

Independent testing plus vendor-level trend data. Community-funded, unaffiliated.

peptidemeter.com
More in c/glp1science
c/glp1science rules
  1. Cite the paper: journal, year, first author. Links optional, citation mandatory.
  2. Mechanistic speculation is welcome if flaired as speculation.
  3. No extrapolating rodent data to human dosing without saying that is what you are doing.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/incretin_ivyu/trialwatch_theou/gastric_emptying_gu/sig_figs_sam
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →